scholarly journals A Randomized Trial Comparing the Efficacy and Safety of Intravitreal Triamcinolone With Observation to Treat Vision Loss Associated With Macular Edema Secondary to Central Retinal Vein Occlusion

2009 ◽  
Vol 127 (9) ◽  
pp. 1101 ◽  
Keyword(s):  
Randomized Trial ◽  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Vision Loss ◽  
Efficacy And Safety ◽  
Intravitreal Triamcinolone ◽  
Vein Occlusion ◽  
Central Retinal Vein

Steroids in the Treatment of Central Retinal Vein Occlusion

2020 ◽  
pp. 139-144
Author(s):  
Alan D. Penman ◽  
Kimberly W. Crowder ◽  
William M. Watkins
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Vision Loss ◽  
Standard Of Care ◽  
Vascular Endothelial ◽  
Intravitreal Triamcinolone ◽  
Vein Occlusion ◽  
Endothelial Growth Factor ◽  
Central Retinal Vein

The Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE-CRVO) Study was a randomized clinical trial comparing intravitreal triamcinolone to observation in eyes with vision loss associated with macular edema due to perfused (nonischemic) central retinal vein occlusion (CRVO). The results suggested that intravitreal triamcinolone in a 1-mg dose should be considered for up to 1 year, and possibly 2 years, in patients with vision loss associated with macular edema secondary to CRVO. The study was the first to establish an effective treatment for perfused CRVO. (Treatment with intravitreal anti–vascular endothelial growth factor [VEGF] agents has been shown to produce greater improvement in visual acuity and is now the standard of care.)

Sign in / Sign up

Export Citation Format

Share Document